Synthesis, radioiodination and in vitro and in vivo sigma receptor studies of N-1-allyl-ND́-4-phenethylpiperazine analogs

Nuclear Medicine and Biology

Volumn 39, Issue 3, 2012, Pages 401-414

  Lever, Susan Z ^a   Xu, Rong ^a   Fan, Kuo Hsien ^a   Fergason Cantrell, Emily A ^b,c   Carmack, Terry L ^a   Watkinson, Lisa D ^a   Lever, John R ^a,b,c  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Allylpiperazines; I 125; Sigma receptors

Indexed keywords

N 1 (3' IODOALLYL) N' 4 (3'' METHOXY 4'' HYDROXYPHENETHYL)PIPERAZINE; N 1 (3' IODOALLYL) N' 4 (3'',4'' DIMETHOXYPHENETHYL)PIPERAZINE; N 1 (3' IODOALLYL) N' 4 (3'',4'' DIMETHOXYPHENETHYL)PIPERAZINE I 125; N 1 ALLYL N' 4 (3',4' DIMETHOXYPHENETHYL)PIPERAZINE; PIPERAZINE DERIVATIVE; SIGMA OPIATE RECEPTOR; SIGMA OPIATE RECEPTOR 1; SIGMA OPIATE RECEPTOR 2; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GUINEA PIG; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; RADIOACTIVITY; RADIOIODINATION; RECEPTOR AFFINITY;

ANIMALS; BINDING, COMPETITIVE; BRAIN CHEMISTRY; IODINE RADIOISOTOPES; LIGANDS; MALE; MICE; MOLECULAR STRUCTURE; PIPERAZINES; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, SIGMA; TISSUE DISTRIBUTION;

EID: 84858157739     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.10.001     Document Type: Article

References (49)

1. Cobos E.J., Entrena J.M., Nieto F.R., Cendán C.M., Del Pozo E. Pharmacology and therapeutic potential of sigma1 receptor ligands. Curr Neuropharmacol 2008, 6:344-366.
2. Maurice T., Su T.P. The pharmacology of sigma-1 receptors. Pharmacol Ther 2009, 124:195-206.
3. Hayashi T., Tsai S.Y., Mori T., Fujimoto M., Su T.P. Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin Ther Targets 2011, 15:557-577.
4. Monnet F.P., Maurice T. The sigma1 protein as a target for the non-genomic effects of neuro(active)steroids: molecular, physiological, and behavioral aspects. J Pharmacol Sci 2006, 100:93-118.
5. Fontanilla D., Johannessen M., Hajipour A.R., Cozzi N.V., Jackson M.B., Ruoho A.E. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 2009, 323:934-937.
6. 1 receptor ligand. Expert Opin Ther Targets 2008, 12:45-58.
7. Matsumoto R.R., Liu Y., Lerner M., Howard E.W., Brackett D.J. σ receptors: potential medications development target for anti-cocaine agents. Eur J Pharmacol 2003, 469:1-12.
8. Narayanan S., Mesangeau C., Poupaert J.H., McCurdy C.R. Sigma receptors and cocaine abuse. Curr Top Med Chem 2011, 11:1128-1150.
9. Rodvelt K.R., Lever S.Z., Lever J.R., Blount L.R., Fan K.H., Miller D.K. SA 4503 attenuates cocaine-induced hyperactivity and enhances methamphetamine substitution for a cocaine discriminative stimulus. Pharmacol Biochem Behav 2011, 97:676-682.
10. Sabino V., Cottone P., Blasio A., Iyer M.R., Steardo L., Rice K.C., et al. Activation of σ-receptors induces binge-like drinking in Sardinian alcohol-preferring rats. Neuropsychopharmacol 2011, 36:1207-1218.
11. Aydar E., Palmer C.P., Djamgoz M.B. Sigma receptors and cancer: possible involvement of ion channels. Cancer Res 2004, 64:5029-5035.
12. Hashimoto K., Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 2006, 12:3857-3876.
13. Hornick J.R., Xu J., Vangveravong S., Tu Z., Mitchem J.B., Spitzer D., et al. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol Cancer 2010, 9. art. no.298.
14. Collier T.L., Waterhouse R.N., Kassiou M. Imaging sigma receptors: applications in drug development. Curr Pharm Design 2007, 13:51-72.
15. 123I]-1-(iodopropen-2-yl)-4-[(4-cyanophenoxy)methyl]piperidine. J Med Chem 1997, 40:1657-1667.
16. 123I]TPCNE-a novel SPET tracer for the sigma-1 receptor: first human studies and in vivo haloperidol challenge. Synapse 2006, 60:109-117.
17. 18F]-(2-fluoroethyl)-4-[(4-cyanophenoxy)methyl]piperidine as a potential radiotracer for PET assessment of CNS sigma-1 receptors. Nucl Med Biol 2006, 33:211-215.
18. 1 receptors. Nucl Med Biol 2000, 27:255-261.
19. 2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse 2006, 59:350-358.
20. 2-like receptors. Ann Nucl Med 2006, 20:569-573.
21. 11C]SA4503. Biol Psychiatry 2007, 62:878-883.
22. 11C]SA4503. Neuroimage 2007, 35:1-8.
23. 18F]fluorinated sigma receptor ligands in the conscious monkey brain. Synapse 2004, 52:29-37.
24. 11C]SA4503. Int J Neuropsychopharmacol 2009, 12:1127-1131.
25. Waterhouse R.N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003, 5:376-389.
26. Lever S.Z., Xu R., Fergason E.A., Carmack T.L., Watkinson L.D., Lever J.R. Synthesis, binding studies and biodistribution of novel radioiodinated sigma-1 receptor ligands. J Nucl Med 2007, 48:246.
27. Lever J.R., Watkinson L.D., Fergason E.A., Carmack T.L., Violand S.A., Lever S.Z. Cocaine occupancy of sigma-1 receptors in vivo 2007.
28. Mach R.H., Huang Y., Freeman R.A., Wu L., Vangveravong S., Luedtke R.R. Conformationally-flexible benzamide analogues as dopamine D3 and sigma2 receptor ligands. Bioorg Med Chem Lett 2004, 14:195-202.
29. 125I]RTI-121). Nucl Med Biol 1996, 23:277-284.
30. Musachio J.L., Lever J.R. Vinylstannylated alkylating agents as prosthetic groups for radioiodination of small molecules: design, synthesis, and application to iodoallyl analogues of spiperone and diprenorphine. Bioconjug Chem 1992, 3:167-175.
31. Sadek S.A., Basmadjian G.P., Hsu P.M., Rieger J.A. New selenium-75 labeled radiopharmaceuticals: selenonium analogues of dopamine. J Med Chem 1983, 26:947-950.
32. 2 receptors. Bioorg Med Chem 2008, 16:755-761.
33. 50) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099-3108.
34. Duval R.A., Allmon R.L., Lever J.R. Indium-labeled macrocyclic conjugates of naltrindole: high affinity radioligands for in vivo studies of peripheral δ opioid receptors. J Med Chem 2007, 50:2144-2156.
35. 125I]Iodophenyl)tropane-2 β-carboxylic acid isopropyl ester. Mol Pharm 1995, 47:779-786.
36. Hirano K., Kimura R., Sugimoto Y., Yamada J., Uchida S., Kato Y., et al. Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol 2005, 144:695-702.
37. 3H]nisoxetine: a new radioligand for norepinephrine uptake sites in brain. Eur J Pharmacol 1990, 191:239-243.
38. 1 receptors of guinea pig brain. Synapse 2005, 55:192-195.
39. Kovács K.J., Larson A.A. Discrepancies in characterization of σ sites in the mouse central nervous system. Eur J Pharmacol 1995, 285:127-134.
40. Matsumoto R.R., Hewett K.L., Pouw B., Bowen W.D., Husbands S.M., Cao J.J., et al. Rimcazole analogs attenuate the convulsive effects of cocaine: correlation with binding to sigma receptors rather than dopamine transporters. Neuropharmacology 2001, 41:878-886.
41. 3H](+)-pentazocine to sigma recognition sites in guinea pig brain. Eur J Pharmacol 1992, 227:371-378.
42. 2 receptors. Psychopharmacology (Berl) 1993, 112(Suppl1):S40-S54.
43. Matsumoto R.R., Bowen W.D., Tom M.A., Vo V.N., Truong D.D., De Costa B.R. Characterization of two novel σ receptor ligands: antidystonic effects in rats suggest σ receptor antagonism. Eur J Pharmacol 1995, 280:301-310.
44. 2-receptor ligands. J Nucl Med 2006, 47:1041-1048.
45. 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 1994, 268:9-18.
46. Obach R.S., Pablo J.P., Mash D.C. Cytochrome P4502D6 catalyzes O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metab Dispos 1998, 26:764-768.
47. Miksys S., Tyndale R.F. Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition. Neuropsychopharmacology 2009, 34:634-640.
48. Baumann M.H., Rothman R.B., Pablo J.P., Mash D.C. In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther 2001, 297:531-539.
49. 2-like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic. Psychopharmacology 1999, 146:81-86.